Key risks include clinical trial failure, regulatory delays, and potential declines in medical tourism demand. The project mitigates these with multi-country trials, adaptive trial designs, parallel regulatory filings, and diversified service offerings.
2026–2027: Multi-site trials in Palau, UAE, and Japan; pilot medical tourism 2028–2029: Phase III trials in UAE, Japan, and the U.S.; regulatory submissions 2030: Global rollout with ~20,000 medical tourism patients annually
A total of 500 million GDT will be minted at launch, with no future issuance. Allocation includes 30% to early investors, 20% to the public sale, 20% for staking/rewards, 10% to the team, 10% to liquidity pools, and 10% to an SDG public fund.
GDT is required for payments in medical tourism, biomarker testing, and 5-ALA supplement purchases. Real-world healthcare demand ensures continuous token usage, and 20% of tokens used for medical services are permanently burned, reducing supply over time.
Biozipcode™ uses a unique 7-amino-acid “cell postal code” that delivers drugs only to the intended target cells, preventing exposure to healthy tissues. This greatly reduces side effects while maintaining high efficacy.
The project aims to prove a complete cure for diabetes by targeting and eliminating abnormal hematopoietic stem cells, known as Diabetes Stem Cells (DSCs), using a combination of HDAC inhibitors, 5-ALA, and Biozipcode™ drug delivery technology.
GDT is a blockchain-based utility token that grants access to specific healthcare services—such as curative diabetes treatment programs, biomarker testing, medical tourism, and specialist consultations—within the Biozipcode Group ecosystem. It is not a security, and it does not provide dividends, interest, or voting rights.
The Biozipcode Group is a project team led by Biozipcode, Inc. (Japan), composed of multiple affiliated companies and institutions involved in medical research, pharmaceutical development, business implementation, international collaboration, and token operations. Research and development are carried out in partnership with academic institutions in Japan, while manufacturing and implementation are handled by partner companies in ...
Utility Token A blockchain-based token that grants access to specific services—such as paying platform fees, unlocking premium features, or settling medical-tour payments—without conferring dividends or voting rights. Its value is driven mainly by actual demand and limited supply; regulatory frameworks usually treat it as non-security when properly structured. Security Token A digital asset representing an ...
Biozipcode™ is a peptide-based drug delivery technology that attaches a “cell-specific postal code” to drugs or diagnostic probes, enabling them to reach only the intended target cells. From combinations of 20 amino acids, seven-digit sequences are designed—yielding over 1.3 billion theoretical combinations—and a code is selected that can be uniquely recognized by the target cell. ...
Global Development Token (GDT) is issued by Auring Inc. (BVI) and operated by the Biozipcode Group, advancing curative diabetes research, medical tourism, and global healthcare innovation.
© 2023 – 2025 Global Development Token All Rights Reserved. | Powered by Studio Makyu Co., Ltd. & Biozipcode Group.
